Abstract: A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid.

Abstract: Disclosed is a method of improving the cognitive function of a cognitively healthy human adult, the method comprising administering to the human adult an effective amount of a composition comprising lutein, zeaxanthin and meso-zeaxanthin and at least one omega-3 fatty acid, over a period of at least 24 months, the improved cognitive function being a detectable improvement in: spatial working memory as measured by the CANTAB Connect Research software SWM task; and/or reduced reaction time as measured by the CANTAB Connect Research Software RTI task.

Abstract: A method for the prevention and/or treatment of mild cognitive impanment in a human subject; the method comprising the step of administering an effective amount of a composition comprising each of the following: lutein, zeaxanthin, meso-zeaxanthin, vitamin E, and at least one omega-3 fatty acid.

Abstract: A method for the prevention and/or treatment of dementia in a human subject; the method comprising the step of administering an effective amount of a composition comprising at least one carotenoid selected from the group consisting of lutein, zeaxanthin and meso-zeaxanthin; and a composition comprising at least one omega-3 fatty acid.

Abstract: A method of identifying a human subject, more likely than a subject selected at random from the general population, to have one or more of the following: (i) a low macular pigment concentration in the eye or eyes; (ii) a low visual performance, or (iii) an atypical “central dip” macular pigment distribution; the method comprising the steps of: measuring at least one cognitive function of the subject; comparing the measured cognitive function with a pre-determined threshold; and, if the measured cognitive function is below the threshold, declaring the subject as being more likely to have one or more of low macular pigment concentration in the eye or eyes, low visual performance or an atypical ‘central dip’ macular pigment profile.

Abstract: Systems and methods may be provided for improving the visual performance of a human subject without the need to test the macular pigment concentration in the eye or eyes of the subject. The method may include identifying a subject likely to have an atypical ‘central dip’ macular pigment distribution; and administering an amount of a macular pigment-containing composition sufficient to improve the visual performance of the subject. Identifying a human subject, more likely than a subject selected at random from the general population, to have an atypical ‘central’ dip macular pigment distribution may include measuring at least one cognitive function of the subject; comparing the measured cognitive function with a pre-determined threshold; and, if the measured cognitive function is below the threshold, declaring the subject as being more likely to have an atypical ‘central dip’ macular pigment profile.